

Ronald Levy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8167799/ronald-levy-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213
papers

17,080
citations

52
h-index

130
g-index

222
ext. papers

19,632
ext. citations

6.8
avg, IF

6.26
L-index

#	Paper	IF	Citations
213	CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity.. <i>Blood Cancer Discovery</i> , 2022 ,	7	10
212	Neoadjuvant Intratumoral Immunotherapy with TLR9 Activation and Anti-OX40 Antibody Eradicates Metastatic Cancer.. <i>Cancer Research</i> , 2022 ,	10.1	2
211	Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. <i>Blood</i> , 2021 , 138, 3539-3539	2.2	
210	In Situ Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions. <i>Blood</i> , 2021 , 138, 2407-2407	2.2	
209	In Situ Vaccination with IL-12Fc and TLR Agonist - a Crucial Role for B Cells in Generating Anti-Tumor T Cell Immunity. <i>Blood</i> , 2021 , 138, 3514-3514	2.2	0
208	Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression. <i>Cell Chemical Biology</i> , 2021 ,	8.2	2
207	Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 2064-2064	2.2	
206	An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory 2021 ,		3
205	Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. <i>Blood</i> , 2021 , 137, 2869-2880	2.2	9
204	An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory. <i>ACS Central Science</i> , 2021 , 7, 1191-1204	16.8	8
203	Targeting the tetraspanin CD81 reduces cancer invasion and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	8
202	How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021 , 2, 562-567	7	6
201	Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. <i>European Journal of Cancer</i> , 2020 , 136, 4-6	7.5	37
200	Intratumoral Immunotherapy for Early-stage Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 3091-3099	12.9	31
199	Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1664-1675	2.2	10
198	Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma. <i>American Journal of Hematology</i> , 2020 , 95, 510-520	7.1	20
197	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 Non-Hodgkin Lymphomas. <i>Clinical Cancer Research</i> , 2020 , 26, 2524-2534	12.9	20

196	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma 2020 , 8,		3
195	Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 48-48	2.2	3
194	Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination. <i>Blood</i> , 2020 , 136, 36-37	2.2	1
193	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. <i>Journal of Experimental Medicine</i> , 2020 , 217,	16.6	8
192	Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. <i>Blood Advances</i> , 2020 , 4, 4244-4255	7.8	12
191	Local Delivery of , , and mRNA Kindles Global Anticancer Immunity. <i>Cancer Research</i> , 2019 , 79, 1624-1634	10.1	50
190	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2019 , 7, 355-362	12.5	49
189	CD81 is a novel immunotherapeutic target for B cell lymphoma. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1497-1508	16.6	13
188	Predicting HLA class II antigen presentation through integrated deep learning. <i>Nature Biotechnology</i> , 2019 , 37, 1332-1343	44.5	112
187	Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation. <i>Blood</i> , 2019 , 134, 84-84	2.2	1
186	Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing. <i>Blood</i> , 2019 , 134, 297-297	2.2	4
185	A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 2825-2825	2.2	
184	Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination. <i>Blood</i> , 2019 , 134, 1479-1479	2.2	
183	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. <i>Blood</i> , 2019 , 133, 1119-1129	2.2	45
182	B-cell lymphomas present immunoglobulin neoantigens. <i>Blood</i> , 2019 , 133, 878-881	2.2	25
181	T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins. <i>Proteomics</i> , 2018 , 18, e1700410	4.8	10
180	Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. <i>Cell Stem Cell</i> , 2018 , 22, 501-513.e718	7.8	78
179	Eradication of spontaneous malignancy by local immunotherapy. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	212

178	Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. <i>Scientific Reports</i> , 2018 , 8, 2278	4.9	16
177	Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018 , 8, 1258-1269	24.4	78
176	Imaging activated T cells predicts response to cancer vaccines. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2569-2580	15.9	74
175	Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma. <i>Blood</i> , 2018 , 132, 1612-1612	2.2	
174	In Situ Vaccination with Cpg and Anti-OX40 Antibody: Preclinical Optimization for Clinical Translation. <i>Blood</i> , 2018 , 132, 2943-2943	2.2	1
173	Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial. <i>Blood</i> , 2018 , 132, 4107-4107	2.2	
172	T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling. <i>Clinical Cancer Research</i> , 2018 , 24, 870-881	12.9	45
171	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2845-2853	2.2	164
170	mRNA vaccination with charge-altering releasable transporters elicits human T cell responses and cures established tumors in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9153-E9161	11.5	60
169	Enhancing immunotherapy of STING agonist for lymphoma in preclinical models. <i>Blood Advances</i> , 2018 , 2, 2230-2241	7.8	26
168	CD81 as a tumor target. <i>Biochemical Society Transactions</i> , 2017 , 45, 531-535	5.1	22
167	Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. <i>Nature</i> , 2017 , 543, 723-727	50.4	161
166	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. <i>Blood</i> , 2017 , 129, 759-770	2.2	52
165	Epstein-Barr virus-positive follicular lymphoma. <i>Modern Pathology</i> , 2017 , 30, 519-529	9.8	26
164	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 2531-2544	59.2	2326
163	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017 , 23, 1929-1936	12.9	181
162	Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma. <i>Blood</i> , 2017 , 130, 826-826	2.2	3
161	Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. <i>Science Translational Medicine</i> , 2016 , 8, 364ra155	17.5	231

160	Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1089-1089	2.2	7
159	Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA. <i>Blood</i> , 2016 , 128, 1752-1752	2.2	6
158	In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma. <i>Blood</i> , 2016 , 128, 1847-1847	2.2	2
157	DNA Copy Number Gains of TCF4 (E2-2) Are Associated with Poor Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2686-2686	2.2	1
156	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. <i>Blood</i> , 2016 , 128, 2974-2974	2.2	5
155	Identification of Tigit on Intra-Tumor T Cells As a New Target for Immune Checkpoint Blockade in Follicular Lymphoma. <i>Blood</i> , 2016 , 128, 917-917	2.2	1
154	Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7511-7511	2.2	2
153	Noninvasive molecular subtyping and risk stratification of DLBCL.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7554-7554	2.2	1
152	Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cytometry in Previously Untreated Patients. <i>Blood</i> , 2016 , 128, 2947-2947	2.2	
151	Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2930-2930	2.2	1
150	Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations. <i>Blood</i> , 2016 , 128, 4107-4107	2.2	
149	Treating B Cell Lymphomas with Anti CD81 Antibodies. <i>Blood</i> , 2016 , 128, 4180-4180	2.2	
148	Massively Parallel Single Cell RNA-Seq of Primary Lymphomas Reveals Distinct Cellular Lineages and Diverse, Intratumoral Transcriptional States. <i>Blood</i> , 2016 , 128, 1090-1090	2.2	
147	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , 2016 , 5, e1186323	7.2	2
146	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia 2016 , 4, 90		14
145	Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis. <i>Oncolimmunology</i> , 2016 , 5, e1120399	7.2	8
144	Targeting lymphoma with precision using semisynthetic anti-idiotypic peptibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 5376-81	11.5	13
143	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E966-72	11.5	295

142	Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E1116-25	11.5	232
141	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. <i>Blood</i> , 2015 , 125, 3679-87	2.2	190
140	Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. <i>Cancer Research</i> , 2015 , 75, 4517-26	10.1	49
139	Current clinical trials testing combinations of immunotherapy and radiation. <i>Seminars in Radiation Oncology</i> , 2015 , 25, 54-64	5.5	103
138	Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma. <i>Blood</i> , 2015 , 125, 2079-86	2.2	54
137	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015 , 125, 2175-7	2.2	16
136	Development of a Novel Virus-like Particle (VLP) Vaccine for Personalized B-Cell Lymphoma and Chronic Lymphocytic Leukemia Therapy. <i>Blood</i> , 2015 , 126, 2748-2748	2.2	3
135	A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3004-3004	2.2	15
134	Phase I/II study of intratumoral injection of SD-101, an immunostimulatory CpG, and intratumoral injection of ipilimumab, an anti-CTLA-4 monoclonal antibody, in combination with local radiation in low-grade B-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8604-TPS8604	2.2	3
133	Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8539-8539	2.2	
132	Distinct early response dynamics of circulating tumor DNA and circulating tumor cells during therapy of B-cell NHL.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8570-8570	2.2	
131	T Regulatory Cells Exhibit Surface Expression of FoxP3 Derived Peptides Presented within Class I MHC. <i>Blood</i> , 2015 , 126, 2228-2228	2.2	
130	Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. <i>Blood</i> , 2015 , 126, 1539-1539	2.2	
129	Translational medicine in action: anti-CD20 therapy in lymphoma. <i>Journal of Immunology</i> , 2014 , 193, 1519-24	3.4	41
128	Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1797-803	2.2	59
127	A brief personal history of cancer immunotherapy at Stanford: if these walls could talk□ <i>Immunologic Research</i> , 2014 , 58, 277-81	4.3	1
126	Targeting CD137 enhances the efficacy of cetuximab. <i>Journal of Clinical Investigation</i> , 2014 , 124, 2668-82	5.9	137
125	New insights into the mechanism of action of immune checkpoint antibodies. <i>OncolImmunology</i> , 2014 , 3, e954869	7.2	9

124	Abstract 2941: Local tumor irradiation combined with PD-1 immune checkpoint inhibition results in local and systemic anti-tumor responses: Successful translation of a mouse model to a human case series 2014 ,		4
123	Combination Immunotherapy of Advanced Lymphoma with Oncolytic Vaccinia Virus and Checkpoint Inhibitor Following Local Tumor Irradiation. <i>Blood</i> , 2014 , 124, 4487-4487	2.2	1
122	A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3007-3007	2.2	36
121	Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3017-3017	2.2	7
120	Joint modeling and registration of cell populations in cohorts of high-dimensional flow cytometric data. <i>PLoS ONE</i> , 2014 , 9, e100334	3.7	37
119	Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8504-8504	2.2	
118	Generating Chimeric Antigen Receptors Utilizing Novel Anti-CD3 Nanobeads. <i>Blood</i> , 2014 , 124, 5949-5949	2.2	2
117	High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. <i>Blood</i> , 2013 , 121, 1367-76	2.2	131
116	Cancer vaccines and T cell therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S97-S101	4.7	8
115	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. <i>Blood</i> , 2013 , 122, 981-7	2.2	173
114	Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. <i>Clinical Cancer Research</i> , 2013 , 19, 5261-3	12.9	44
113	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2447-63	15.9	285
112	Potentiated B-Cell Antigen Receptor Signaling In Mantle Cell Lymphoma Is Associated With Overexpression Of Surface CD79B and IgM. <i>Blood</i> , 2013 , 122, 1768-1768	2.2	2
111	Immunotransplant Expands Vaccine-Induced Memory T Cell Responses In Patients With Mantle Cell Lymphoma. <i>Blood</i> , 2013 , 122, 1816-1816	2.2	1
110	Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity. <i>Blood</i> , 2013 , 122, 373-373	2.2	8
109	Anti-KIR Antibody Enhancement Of Anti-Lymphoma Activity Of Natural Killer Cells As Monotherapy and In Combination With Anti-CD20 Antibodies. <i>Blood</i> , 2013 , 122, 4417-4417	2.2	1
108	B-Cell Receptors Of Follicular Lymphoma Patients Recognize Themselves. <i>Blood</i> , 2013 , 122, 633-633	2.2	1
107	Targeting CD137 to enhance the antitumor efficacy of cetuximab by stimulation of innate and adaptive immunity.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3015-3015	2.2	3

106	A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3107-TPS3107	2.2	7
105	A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS3108-TPS3108	2.2	6
104	An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS8614-TPS8614	2.2	1
103	High-Throughput Sequencing Of T Cell Receptors Detects Signatures Of T Cell Repertoire That Predict MRD Status In Patients With Mantle Cell Lymphoma Undergoing Immunotransplantation. <i>Blood</i> , 2013 , 122, 4251-4251	2.2	
102	CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. <i>American Journal of Pathology</i> , 2012 , 181, 795-803	5.8	42
101	Combination strategies to enhance antitumor ADCC. <i>Immunotherapy</i> , 2012 , 4, 511-27	3.8	71
100	Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. <i>OncImmunology</i> , 2012 , 1, 957-958	7.2	22
99	A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 14526-31	11.5	39
98	Complementary costimulation of human T-cell subpopulations by cluster of differentiation 28 (CD28) and CD81. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 1613-8	11.5	23
97	Deep B and T Cell Repertoire Sequencing to Evaluate Minimal Residual Disease and T Cell Responses in a Therapeutic Vaccine Trial for Mantle Cell Lymphoma. <i>Blood</i> , 2012 , 120, 582-582	2.2	3
96	in Situ Vaccination for Patients with Previously Untreated Follicular Lymphoma: Analysis of Immune Responses. <i>Blood</i> , 2012 , 120, 3703-3703	2.2	
95	Targeting B-Cell Lymphoma with Idiotype-Specific Peptibodies: Toward a Personalized and Tumor-Specific Therapy. <i>Blood</i> , 2012 , 120, 3713-3713	2.2	
94	Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma. <i>Blood</i> , 2012 , 120, 148-148	2.2	
93	Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. <i>Trends in Immunology</i> , 2011 , 32, 510-6	14.4	50
92	CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. <i>Blood</i> , 2011 , 117, 2423-32		170
91	A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. <i>Blood</i> , 2011 , 117, 118-27	2.2	35
90	Immunomodulating antibodies and drugs for the treatment of hematological malignancies. <i>Cancer and Metastasis Reviews</i> , 2011 , 30, 97-109	9.6	14
89	Immunotransplant for Mantle Cell Lymphoma: Phase I/II Study Preliminary Results. <i>Blood</i> , 2011 , 118, 3068-3068	2.2	

88	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 2578-85	2.2	612
87	Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. <i>American Journal of Clinical Pathology</i> , 2010 , 134, 278-81	1.9	8
86	In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4324-32	2.2	376
85	NF-B Signaling In Response to CpG Stratifies Mantle Cell Lymphoma Patient Outcome. <i>Blood</i> , 2010 , 116, 144-144	2.2	2
84	Clinical Translation of a Prognostic Follicular Lymphoma Signaling Profile. <i>Blood</i> , 2010 , 116, 636-636	2.2	
83	CD137 Identifies a Population of Regulatory T Cells That Inhibit Anti-Tumor Immune Responses In Adoptive Immunotherapy. <i>Blood</i> , 2010 , 116, 2093-2093	2.2	
82	Clinical and Pathological Features of Non-Hodgkin Lymphomas Harboring Concurrent t(14;18) and 8q24 Anomalies. <i>Blood</i> , 2010 , 116, 3134-3134	2.2	
81	Prediction of Survival In Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes Reflecting Tumor and Microenvironment. <i>Blood</i> , 2010 , 116, 2006-2006	2.2	
80	Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009 , 50, 37-46	1.9	35
79	Idiotype vaccination for lymphoma: moving towards optimisation. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1-2	1.9	9
78	Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. <i>Immunotherapy</i> , 2009 , 1, 809-24	3.8	9
77	Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. <i>International Journal of Cancer</i> , 2009 , 124, 239-44	7.5	61
76	Cell-free production of Gaussia princeps luciferase-antibody fragment bioconjugates for ex vivo detection of tumor cells. <i>Biochemical and Biophysical Research Communications</i> , 2009 , 390, 971-6	3.4	20
75	T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. <i>Blood</i> , 2009 , 113, 3546-52	2.2	144
74	Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. <i>Blood</i> , 2009 , 113, 5743-6	2.2	47
73	Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. <i>Blood</i> , 2009 , 114, 3431-8	2.2	101
72	Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Xenografts.. <i>Blood</i> , 2009 , 114, 2716-2716	2.2	1
71	A Subpopulation of Follicular Lymphoma Tumor Infiltrating T Cells Shows Suppressed Common Gamma Chain Cytokine Signaling.. <i>Blood</i> , 2009 , 114, 759-759	2.2	3

70	Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Cells to Generate Potent Anti-Tumor CD4 T Cell Immunity.. <i>Blood</i> , 2009 , 114, 929-929	2.2	
69	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. <i>Blood</i> , 2009 , 114, 622-622	2.2	1
68	Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 2951-2951	2.2	
67	Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 2712-2712	2.2	
66	Adoptive Therapy for Lymphoma with CD4 Memory T Cells Depleted of CD137-Expressing Tregs.. <i>Blood</i> , 2009 , 114, 1693-1693	2.2	
65	Expression of the human germinal-centre-associated lymphoma protein in diffuse large B-cell lymphomas in patients with rheumatoid arthritis. <i>British Journal of Haematology</i> , 2008 , 141, 69-72	4.5	18
64	A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6697-703	12.9	133
63	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , 2008 , 111, 5509-14	2.2	80
62	The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms with rare exceptions. <i>FASEB Journal</i> , 2008 , 22, 902.15	0.9	
61	Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. <i>Journal of Immunology</i> , 2007 , 179, 2493-500	5.3	106
60	Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. <i>Blood</i> , 2007 , 109, 3393-9	2.2	101
59	Survival in Follicular Lymphoma: The Stanford Experience, 1960-2003.. <i>Blood</i> , 2007 , 110, 3428-3428	2.2	7
58	Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.. <i>Blood</i> , 2007 , 110, 49-49	2.2	1
57	LMO2 Protein Expression Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma in the Pre- and Post-Rituximab Treatment Eras.. <i>Blood</i> , 2007 , 110, 52-52	2.2	2
56	Preferential Proliferation of T Effectors and Tumor Protection by Adoptive Transfer of Primed Anti-Lymphoma Splenocytes into Lymphodepleted Hosts.. <i>Blood</i> , 2007 , 110, 2753-2753	2.2	
55	Anti-Idiotype Antibody Response after Vaccination Correlates with Better Overall Survival in Follicular Lymphoma.. <i>Blood</i> , 2007 , 110, 647-647	2.2	
54	Gene-Specific Delineation of Copy Number Aberrations in Follicular Lymphoma with Molecular Inversion Probes.. <i>Blood</i> , 2007 , 110, 2603-2603	2.2	
53	Correlation of IFN- γ /CD107 and CD137 at the Single Cell Level Can Be Used To Monitor T Cell Responses in Patients after Immunotherapy.. <i>Blood</i> , 2007 , 110, 2306-2306	2.2	

52	Efficient Transfer of CD40L mRNA into Mantle Cell Lymphoma for the Production of a Whole Tumor Cell Vaccine.. <i>Blood</i> , 2007 , 110, 2591-2591	2.2	
51	Preliminary Report on a Phase I/II Study of Intratumoral Injection of PF-3512676 (CpG 7909), a TLR9 Agonist, Combined with Radiation in Recurrent Low-Grade Lymphomas.. <i>Blood</i> , 2006 , 108, 2716-2716	2.2	2
50	Tumor-Infiltrating T Cells Are Not Predictive of Clinical Outcome in Follicular Lymphoma.. <i>Blood</i> , 2006 , 108, 824-824	2.2	3
49	The Oncoprotein LMO2 Is Expressed in a Germinal Center B-Cell-Associated Pattern and Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 810-810	2.2	
48	Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. <i>Biotechnology and Bioengineering</i> , 2005 , 89, 503-11	4.9	66
47	Long-Term Follow-Up of Patients Treated in a Phase 2 Trial with MyVax [®] Personalized Immunotherapy (Recombinant Id-KLH with GM-CSF) after Chemotherapy as Initial Treatment for Follicular Non-Hodgkin [®] Lymphoma (NHL).. <i>Blood</i> , 2005 , 106, 2438-2438	2.2	6
46	A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.. <i>Blood</i> , 2005 , 106, 778-778	2.2	3
45	CpG in the Immunotherapy of B-Cell Lymphoma.. <i>Blood</i> , 2005 , 106, 344-344	2.2	
44	Expression of the Human Germinal Center Associated Lymphoma (HGAL) Protein Identifies a Subset of Classical Hodgkin Lymphoma of Germinal Center Derivation and Improved Outcome.. <i>Blood</i> , 2005 , 106, 23-23	2.2	
43	Anti-Tumor Effect of Direct Intratumor Injection of Recombinant Fowlpox Virus Encoding CD40 Ligand in B Cell Lymphoma Model.. <i>Blood</i> , 2005 , 106, 1477-1477	2.2	
42	RNA-Binding Protein VICKZ Is Expressed in a Germinal Center Associated Pattern among Lymphoma Subtypes.. <i>Blood</i> , 2005 , 106, 1909-1909	2.2	
41	Cancer vaccines: pessimism in check. <i>Nature Medicine</i> , 2004 , 10, 1279; author reply 1279-80	50.5	16
40	A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin [®] Lymphoma.. <i>Blood</i> , 2004 , 104, 3279-3279	2.2	5
39	The Number of CD25+ Tumor-Infiltrating Cells May Predict Clinical Response to Rituximab in Follicular Lymphoma Patients.. <i>Blood</i> , 2004 , 104, 748-748	2.2	6
38	Immunoglobulin G Fc Polymorphism Is Correlated with Rituximab-Induced Neutropenia Following Autologous Hematopoietic Cell Transplantation.. <i>Blood</i> , 2004 , 104, 442-442	2.2	1
37	The Percentage of Tumor-Infiltrating T Cells Is Not Correlated with Overall Survival in Follicular B-Cell Lymphomas.. <i>Blood</i> , 2004 , 104, 3262-3262	2.2	
36	Immunoglobulin G Fc Receptor Polymorphisms and Clinical Course in Follicular Lymphoma Patients.. <i>Blood</i> , 2004 , 104, 3250-3250	2.2	
35	A Novel Method for Producing Custom-Made Idiotype Vaccines for Lymphoma Immunotherapy Using a Cell-Free Expression System.. <i>Blood</i> , 2004 , 104, 1410-1410	2.2	

34	Vaccines in lymphoma. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 424, 427	0.6	
33	Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. <i>Blood</i> , 2003 , 101, 3109-17	2.2	196
32	Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2003 , 21, 3940-7	2.2	1112
31	Analysis of FAS (CD95) gene mutations in higher-grade transformation of follicle center lymphoma. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1317-23	1.9	9
30	Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 8886-91	11.5	190
29	Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2001 , 98, 945-51	2.2	251
28	Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. <i>Blood</i> , 2001 , 98, 1352-7	2.2	189
27	A polymorphism in the BCL-6 gene is associated with follicle center lymphoma. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1343-50	1.9	5
26	Mutation analysis of the 5' noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. <i>Blood</i> , 2000 , 95, 1400-1405	2.2	49
25	Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. <i>Blood</i> , 2000 , 96, 635-639	2.2	82
24	Cytokine fusion constructs as DNA vaccines against tumors. <i>Methods in Molecular Medicine</i> , 2000 , 29, 221-39		
23	Dendritic cell vaccines for cancer immunotherapy. <i>Annual Review of Medicine</i> , 1999 , 50, 507-29	17.4	391
22	Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas. <i>Methods in Molecular Biology</i> , 1998 , 87, 209-34	1.4	1
21	Anti-Idiotype Antibodies Can Induce Long-Term Complete Remissions in Non-Hodgkin's Lymphoma Without Eradicating the Malignant Clone. <i>Blood</i> , 1998 , 92, 1184-1190	2.2	144
20	Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma [Long-Term Results of a Clinical Trial. <i>Blood</i> , 1997 , 89, 3129-3135	2.2	419
19	IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. <i>Blood</i> , 1997 , 90, 2188-2195	2.2	1371
18	Idiotype Vaccines for Non-Hodgkin's Lymphoma Induce Polyclonal Immune Responses That Cover Mutated Tumor Idiotypes: Comparison of Different Vaccine Formulations. <i>Blood</i> , 1997 , 90, 3699-3706	2.2	52
17	Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. <i>Nature Medicine</i> , 1996 , 2, 52-8	50.5	1576

16	DNA immunization induces protective immunity against B-cell lymphoma. <i>Nature Medicine</i> , 1996 , 2, 1038-41	5.1	227
15	A submicroscopic interstitial deletion of chromosome 14 frequently occurs adjacent to the t(14;18) translocation breakpoint in human follicular lymphoma. <i>Genes Chromosomes and Cancer</i> , 1993 , 6, 140-50	5	18
14	Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. <i>Nature</i> , 1993 , 362, 755-8	50.4	293
13	Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. <i>New England Journal of Medicine</i> , 1992 , 327, 1209-15	59.2	485
12	DNA fragmentation and cell death mediated by T cell antigen receptor/CD3 complex on a leukemia T cell line. <i>European Journal of Immunology</i> , 1989 , 19, 1911-9	6.1	63
11	Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. <i>International Reviews of Immunology</i> , 1989 , 4, 251-70	4.6	28
10	Quantitation and estimation of lymphocyte subsets in tissue sections. Comparison with flow cytometry. <i>American Journal of Clinical Pathology</i> , 1987 , 87, 470-7	1.9	44
9	Somatic mutations in the Ig VH genes of human B cell lymphoma. <i>Pediatrics International</i> , 1987 , 29, 561-5	2	
8	The optimal application of forward and ninety-degree light scatter in flow cytometry for the gating of mononuclear cells. <i>Cytometry</i> , 1985 , 6, 401-6		46
7	Monoclonal anti-idiotypic antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. <i>Hybridoma</i> , 1985 , 4, 191-209		101
6	Treatment of B-cell lymphoma with monoclonal anti-idiotypic antibody. <i>New England Journal of Medicine</i> , 1982 , 306, 517-22	59.2	817
5	Production in vitro of murine antibody to a human histocompatibility alloantigen. <i>Nature</i> , 1978 , 271, 461-2	50.4	18
4	Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines. <i>Cancer</i> , 1978 , 42, 2379-91	6.4	152
3	Homogeneous antibodies directed against human cell surface antigens: I. The mouse spleen fragment culture response to T and B cell lines derived from the same individual. <i>Journal of Supramolecular Structure</i> , 1977 , 6, 441-8		5
2	Cell-Free Technology for Rapid Production of Patient-Specific Fusion Protein Vaccines	69-82	
1	Charge-Altering Releasable Transporters Enable Specific Phenotypic Manipulation of Resting Primary Natural Killer Cells		2